Axovant ’s Phase III trial of Alzheimer's disease drug fails to meet primary endpoints

Axovant Sciences has reported negative top-line results from its Phase III MINDSET clinical trial of intepirdine conducted to treat mild-to-moderate Alzheimer's disease (AD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news